Aurita Bioscience

Executive Summary

Aurita Bioscience is a preclinical-stage biotechnology company pioneering advanced in vitro immuno-oncology assays that more accurately recapitulate the human tumor microenvironment. Their proprietary iVITA™ platform replaces traditional 2D monolayers with 3D, multicellular models that preserve native cell-cell interactions, matrix architecture, and dynamic reorganization. This approach aims to bridge the gap between simplistic laboratory models and clinical reality, enabling better prediction of therapeutic responses and reducing attrition in drug development. Founded in 2019 and based in Gainesville, Florida, the company operates at the intersection of oncology and immunology, targeting the urgent need for more physiologically relevant tools to evaluate immunotherapies and combination regimens. While still in early stages, Aurita's focus on microenvironmental fidelity positions it as a potential differentiator in the immuno-oncology assay space.

Upcoming Catalysts (preview)

• Q4 2026First major pharma partnership or licensing deal for iVITA platform40% success
• Q2 2026Publication or presentation of validation data in peer-reviewed journal or major conference60% success
• Q3 2026Completion of Series A fundraising round50% success